MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC
NCT07235566
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Thyroid Cancer
Interventions
DRUG:
MRG003 in combination with pucotenlimab
Sponsor
Fudan University